• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Javed Aasim was granted 500,000 shares, increasing direct ownership by 109% to 1,023,476 units (SEC Form 4)

    2/27/24 8:11:48 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $HLTH alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Javed Aasim

    (Last) (First) (Middle)
    C/O CUE HEALTH INC.
    4980 CARROLL CANYON

    (Street)
    SAN DIEGO CA 92121

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Cue Health Inc. [ HLTH ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    02/08/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 02/08/2024 A 300,000(1) A $0 790,645(2) D
    Common Stock 02/08/2024 A 200,000(3) A $0 1,023,476(4) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The reported shares are represented by restricted stock units, or RSUs, which vest in eight equal quarterly installments beginning on June 5, 2024.
    2. Includes 32,831 shares acquired under the Issuer's employee stock purchase plan on December 29, 2023.
    3. The reported shares are represented by RSUs which vest in two equal annual installments beginning on March 5, 2025.
    4. Includes 858,127 unvested RSUs.
    Remarks:
    Exhibit 24 - Power of Attorney
    /s/ Joshua Bergmann, Attorney-in-Fact for Aasim Javed 02/27/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $HLTH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HLTH

    DatePrice TargetRatingAnalyst
    3/14/2024Buy → Neutral
    BTIG Research
    10/19/2021$18.00Buy
    BTIG Research
    10/19/2021$12.00Equal-Weight
    Morgan Stanley
    10/19/2021$19.00Buy
    Goldman Sachs
    10/19/2021$14.00Outperform
    Cowen & Co.
    More analyst ratings

    $HLTH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cue Health to Pursue Wind Down of the Business

      Cue Health Inc. ("Cue" or the "Company") (NASDAQ:HLTH), a healthcare technology company, today announced the Company has filed voluntary petitions under Chapter 7 of the U.S. Bankruptcy Code in the District of Delaware to pursue a wind down of its business. Cue has been working diligently to strengthen the Company's financial foundation, including taking a number of actions to reduce costs and improve operational efficiency. Cue also undertook an extensive process to locate additional financing or effect a strategic transaction. Despite its best efforts and after a comprehensive review, Cue's Board of Directors in consultation with the Company's advisors, has concluded that it is in the b

      5/28/24 4:31:00 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cue Health Evaluating Warning Letter Received from Food and Drug Administration (FDA)

      Cue Health Inc. (NASDAQ:HLTH), a healthcare technology company (the "Company"), has received a warning letter from the FDA about its Emergency Use Authorized (EUA) COVID-19 test. The Company is currently evaluating the letter and determining its response, with more information to follow in the next few days. About Cue Cue Health Inc. (NASDAQ:HLTH) is a healthcare technology company that empowers healthcare providers to streamline their ability to deliver value-based care with fast, highly accurate test results on demand. Cue received De Novo authorization from the U.S. Food and Drug Administration (FDA) for its COVID-19 test, which became the first home use respiratory test to receive t

      5/13/24 8:30:00 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cue Health to Announce First Quarter Financial Results

      Cue Health Inc. ("Cue") (NASDAQ:HLTH), a healthcare technology company, announced today that it will release its first quarter 2024 financial results on Monday, May 13, 2024. The company will not be hosting a conference call. About Cue Health Cue Health Inc. (NASDAQ:HLTH) is a healthcare technology company that uses diagnostic-enabled care to empower people to live their healthiest lives. Cue's platform offers individuals and healthcare providers convenient and personalized access to lab-quality diagnostic tests at home and at the point-of-care, as well as on-demand telehealth consultations and treatment options for a wide range of health and wellness needs. Cue's customers include fede

      4/29/24 4:01:00 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HLTH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • June 6, 2023 - FDA Permits Marketing of First COVID-19 At-Home Test Using Traditional Premarket Review Process

      For Immediate Release: June 06, 2023 Today, the U.S. Food and Drug Administration granted marketing authorization for the Cue COVID-19 Molecular Test. The product is a molecular nucleic acid amplification test (NAAT) that is intended to detect genetic material from SARS-CoV-2 virus present in nasal swabs from adults with signs and symptoms of upper respiratory infection. This test is the first at-home over-the-c

      6/6/23 3:04:14 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HLTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Javed Aasim covered exercise/tax liability with 13,327 shares, decreasing direct ownership by 1% to 998,004 units (SEC Form 4) (Amendment)

      4/A - Cue Health Inc. (0001628945) (Issuer)

      5/21/24 6:29:25 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Sever Clint covered exercise/tax liability with 20,456 shares, decreasing direct ownership by 0.46% to 4,379,914 units (SEC Form 4)

      4 - Cue Health Inc. (0001628945) (Issuer)

      3/27/24 7:29:01 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Pollard Randall E. covered exercise/tax liability with 7,304 shares, decreasing direct ownership by 1% to 503,202 units (SEC Form 4)

      4 - Cue Health Inc. (0001628945) (Issuer)

      3/7/24 8:45:08 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HLTH
    SEC Filings

    See more
    • Cue Health Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Cue Health Inc. (0001628945) (Filer)

      5/28/24 5:02:54 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cue Health Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

      8-K - Cue Health Inc. (0001628945) (Filer)

      5/16/24 4:20:43 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form NT 10-Q filed by Cue Health Inc.

      NT 10-Q - Cue Health Inc. (0001628945) (Filer)

      5/16/24 4:17:26 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HLTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Cue Health Inc. (Amendment)

      SC 13D/A - Cue Health Inc. (0001628945) (Subject)

      5/17/24 3:21:32 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13D/A filed by Cue Health Inc. (Amendment)

      SC 13D/A - Cue Health Inc. (0001628945) (Subject)

      2/21/24 5:00:19 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Cue Health Inc. (Amendment)

      SC 13G/A - Cue Health Inc. (0001628945) (Subject)

      2/14/24 5:09:58 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HLTH
    Leadership Updates

    Live Leadership Updates

    See more
    • Cue Health Announces Strategic Actions to Position Company for Next Stage

      Clint Sever Appointed CEO Board Appoints Two Strategic Advisors Who Bring Significant Industry Expertise Cue Health Inc. ("Cue" or the "Company") (NASDAQ:HLTH), a healthcare technology company, today announced strategic actions implemented by its Board of Directors (the "Board") to best position the Company for its next stage: Clint Sever, co-founder and current Chief Product Officer, has been appointed CEO, effective immediately. Sever succeeds Ayub Khattak, who is stepping down as Chief Executive Officer, President, and Chairman. Khattak will remain a member of the Board of Directors. The Board has appointed two strategic advisors, who have specific subject matter expertise in i

      3/20/24 5:21:00 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cue Health Announces Appointment of Rishi Reddy to Board of Directors

      Cue Health (NASDAQ:HLTH), a healthcare technology company, today announced it entered into a cooperation agreement (the "Cooperation Agreement") with Tarsadia Investments ("Tarsadia"), and appointed Rishi Reddy to its board of directors (the "Board"), effective immediately. Mr. Reddy is a Managing Director at Tarsadia, where he leads the firm's venture and growth equity strategy. He was previously an Observer on Cue's Board of Directors from April 2018 to September 2021. In addition, the Board intends to commence a process to add an additional highly qualified, independent director to the Board. "Cue remains focused on creating value for all of its stakeholders," said Ayub Khattak, Chairm

      2/16/24 5:00:00 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cue Health Announces Appointment of Josh Ghaim, Ph.D. and Sachin Jain, M.D. to its Board of Directors

      Cue Health ("Cue") (NASDAQ:HLTH), a healthcare technology company that puts diagnostic information at the center of care, today announced that Josh Ghaim, Ph.D. and Sachin Jain, M.D. have joined its Board of Directors. Cue Health's Board now consists of seven directors, five of whom are independent. "On behalf of the management team and Board, I'm pleased to welcome both Josh and Sachin to the Cue team. We are excited to have vast knowledge of health plans and payors as well as the perspective of a medical doctor on Cue's Board as we continue to pursue our vision of making healthcare more convenient, accessible, and timely by placing diagnostic information at the center of care," said Ayub

      11/17/22 4:15:00 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HLTH
    Financials

    Live finance-specific insights

    See more
    • Cue Health to Announce First Quarter Financial Results

      Cue Health Inc. ("Cue") (NASDAQ:HLTH), a healthcare technology company, announced today that it will release its first quarter 2024 financial results on Monday, May 13, 2024. The company will not be hosting a conference call. About Cue Health Cue Health Inc. (NASDAQ:HLTH) is a healthcare technology company that uses diagnostic-enabled care to empower people to live their healthiest lives. Cue's platform offers individuals and healthcare providers convenient and personalized access to lab-quality diagnostic tests at home and at the point-of-care, as well as on-demand telehealth consultations and treatment options for a wide range of health and wellness needs. Cue's customers include fede

      4/29/24 4:01:00 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cue Health Reports Fourth Quarter 2023 Financial Results

      Cue Health Inc. ("Cue" or the "Company") (NASDAQ:HLTH), a healthcare technology company, today reported financial results for the fourth quarter and full-year 2023. Recent Highlights Reported fourth quarter total revenue of $18.8 million. Full-year 2023 total revenue was $70.9 million Submitted additional clinical samples and stability data for RSV to the FDA in support of de novo submission Submitted additional clinical samples and gathering additional stability data for Flu A/B to the FDA in support of de novo submission In late stage development of Herpes + Mpox Multiplex Molecular Test with plan to submit for EUA in 2Q24 Executed cost reduction plans, resulting in cash

      3/13/24 4:01:00 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cue Health to Announce Fourth Quarter and Full Year 2023 Financial Results

      Cue Health Inc. ("Cue") (NASDAQ:HLTH), a healthcare technology company, announced today that it will release its fourth quarter and full year 2023 financial results on Wednesday, March 13, 2024. In conjunction with the release, Cue will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique personal PIN that can be used to join the call. The live webinar of the call may be accessed by visiting the Events

      2/28/24 4:01:00 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HLTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cue Health downgraded by BTIG Research

      BTIG Research downgraded Cue Health from Buy to Neutral

      3/14/24 7:38:37 AM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • BTIG Research initiated coverage on Cue Health with a new price target

      BTIG Research initiated coverage of Cue Health with a rating of Buy and set a new price target of $18.00

      10/19/21 9:45:18 AM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Morgan Stanley initiated coverage on Cue Health with a new price target

      Morgan Stanley initiated coverage of Cue Health with a rating of Equal-Weight and set a new price target of $12.00

      10/19/21 8:30:49 AM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials